Skip to search formSkip to main contentSkip to account menu

Invirase

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Medicinal Chemistry is often referred to as a mature science. We believe that this is a misperception. What is probably more… 
Highly Cited
2004
Highly Cited
2004
Saquinavir is a selective HIV protease inhibitor with limited systemic bioavailability (4% for the hard gelatin capsule (Invirase… 
Highly Cited
2002
Highly Cited
2002
AIMS Bioavailability of orally administered drugs depends on several factors including active excretion, e.g. by P-glycoprotein… 
2001
2001
Two studies, concerning the synthesis of original nucleoside analogs regarded as an application of heterochemistry on… 
Review
2000
Review
2000
AbstractBackground: PISCES (SV14604) was the largest study of antiretroviral therapy to assess clinical end-points. The study… 
Review
1998
Review
1998
Cytochrome P450 3A4 (CYP3A4), the major phase I drug metabolizing enzyme in humans, and the MDR1 gene product P-glycoprotein (P… 
1997
1997
The humoral immune response to HIV infection plays an important role in determining disease progression. Few and discordant… 
1996
1996
  • MMWR. Morbidity and mortality weekly report
  • 1996
  • Corpus ID: 25134566
In 1995 and 1996, the Food and Drug Administration (FDA) approved three products in the new protease inhibitor class of drugs… 
1995
1995
  • J. James
  • AIDS treatment news
  • 1995
  • Corpus ID: 42637469
Saquinavir, developed by Hoffmann-LaRoche under the trade name Invirase, is the first protease inhibitor to be approved by the… 
1995
1995
: Saquinavir, developed by Hoffmann-LaRoche under the trade name Invirase, is the first protease inhibitor to be approved by the…